Import Clopidogrel Bisulphate Form I Form Ii 120202-6 — Buy in Bulk from Supplier in China

Clopidogrel bisulphate form I and form II (CAS 120202-66-6) is a pharmaceutical-grade antiplatelet agent supplied by Suzhou Tianma Pharma Group in China. The compound is offered as a high-purity active pharmaceutical ingredient (API) for use in cardiovascular medication formulations, including tablets. Its chemical structure corresponds to the bisulphate salt of clopidogrel, a thienopyridine derivative that inhibits ADP-induced platelet aggregation.

The product meets typical pharmaceutical standards for API purity, with form I and form II representing distinct polymorphic forms that may influence bioavailability and stability. Standard industry specifications for clopidogrel bisulphate include a purity of not less than 98.0% as determined by HPLC, with residual solvents and heavy metals controlled to ICH guidelines. The API is typically supplied as a white to off-white crystalline powder, soluble in water and dimethylformamide.

This API is primarily sourced by pharmaceutical manufacturers developing generic versions of clopidogrel-based drugs for cardiovascular therapy. Buyers typically confirm polymorphic form stability, particle size distribution, and dissolution rates to ensure consistency in final dosage forms. Suzhou Tianma Pharma Group supplies the compound in bulk quantities, with packaging and storage conditions aligned to ICH Q1A stability requirements.

Suzhou Tianma Pharma Group operates from Shanghai, China, as an imported-tier supplier specialising in pharmaceutical intermediates and APIs. The company’s profile indicates a focus on cardiovascular compounds, with clopidogrel bisulphate forming a core part of its product portfolio. No response rate or verification signals are currently recorded for this supplier.

The supplier’s address is confirmed as Shanghai 200080, China, but no additional operational details such as facility size, production capacity, or certifications are provided in the available data. Buyers are advised to request specific documentation, including DMF filings or CEP certificates, directly from Suzhou Tianma Pharma Group to verify compliance with regulatory standards.